Business
Ardelyx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and
About this update from Ardelyx, Inc.
WALTHAM, Mass. , Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Citi Biopharma Back to School Summit Location: Boston, MA Fireside Chat: Wednesday, September 3 at 1:00 p.m. ET 1x1 Meetings: Wednesday, September 3 Cantor Global Healthcare Conference Location: New York, NY Fireside Chat: Thursday, September 4 at 8:35 a.m. ET 1x1 Meetings: Thursday, September 4 Morgan Stanley 23rd Annual Global Healthcare Conference Location: New York, NY Fireside Chat: Monday, September 8 at 7:00 a.m. ET 1x1 Meetings: Monday, September 8 H.C. Wainwright 27th Annual Global Investment Conference Location: New York, NY Presentation: Tuesday, September 9 at 11:30 a.m. ET 1x1 Meetings: Tuesday, September 9 To access the live webcast of the Fireside Chats, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com . A replay of the sessions will be available on the Ardelyx website for 30 days following the event. About Ardelyx Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States , IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan . A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada . For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter) , LinkedIn and Facebook . Investor and Media Contacts: Caitlin Lowie [email protected] Source: Ardelyx, Inc.